CHINA LIFE INSURANCE COMPANY LIMITED |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 11.08 HKD | -1.42% |
|
-5.94% | +9.49% |
| May. 27 | New China Life Insurance Declares 2023 Year-End Dividend | MT |
| May. 22 | Nomura Adjusts China Life Insurance’s Price Target to 19.93 Yuan From 17.80 Yuan, Keeps at Reduce | MT |
Summary
- Overall, the company has poor fundamentals for a medium to long-term investment strategy.
- From a short-term investment perspective, the company presents a deteriorated fundamental situation
Strengths
- Its low valuation, with P/E ratio at 6.94 and 5.93 for the ongoing fiscal year and 2025 respectively, makes the stock pretty attractive with regard to earnings multiples.
- The company appears to be poorly valued given its net asset value.
- This company will be of major interest to investors in search of a high dividend stock.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The opinion of analysts covering the stock has improved over the past four months.
Weaknesses
- According to forecast, a sluggish sales growth is expected for the next fiscal years.
- For the past year, analysts have significantly revised downwards their profit estimates.
- Prospects from analysts covering the stock are not consistent. Such dispersed sales estimates confirm the poor visibility into the group's activity.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Life & Health Insurance
| 1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
|---|---|---|---|---|
| +9.49% | 101B | B- | ||
| +6.87% | 101B | B | ||
| -11.17% | 86.29B | B+ | ||
| +21.65% | 76.75B | D+ | ||
| +21.03% | 34.44B | B | ||
| +20.29% | 30.89B | B | ||
| +13.27% | 29.37B | A | ||
| -3.22% | 16.64B | C+ | ||
| -14.98% | 14.17B | B | ||
| +19.69% | 12.71B | A- |
Investor Rating
Trading Rating
ESG Refinitiv
Financials
Sales growth
Earnings Growth
EBITDA / Sales
-
Profitability
Finances
-
Valuation
P/E ratio
EV / Sales
-
Price to Book
Price to Free Cash Flow
-
Yield
Momentum
1 year Revenue revision
4 months Revenue revision
7 days Revenue revision
1 year EPS revision
4 months EPS revision
Consensus
Analyst Opinion
Potential Price Target
4m Target Price Revision
4m Revision of opinion
12m Revision of opinion
Business Predictability
Analyst Coverage
Divergence of Estimates
Divergence of analysts' opinions
Divergence of Target Price
Earnings quality
Environment
Emissions
Innovation
Use of resources
Governance
CSR Strategy
Management
Shareholders
Controversy
Controversy
Technical analysis
ST Timing
MT Timing
LT Timing
RSI
Bollinger Spread
Unusual volumes
- Stock Market
- Equities
- 2628 Stock
- Ratings China Life Insurance Company Limited
